



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Date: 20 May 2026

| | |
|--|---|
| To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 | To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (E) Mumbai-400051 |
| Security Code: 540596 | Symbol: ERIS |

SUBJECT: OUTCOME OF THE BOARD MEETING HELD TODAY, i.e., MAY 20, 2026

Dear Sir/Madam,

Pursuant to Regulation 30 read with Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“**LODR**”) we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., May 20, 2026, inter alia, duly approved and took on record the following:

- Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026.

In this regard, the following documents are enclosed:

- A copy of the said financial results along with audit report pursuant to Regulation 33 and Regulation 52 of the SEBI Listing Regulations. The audit reports are submitted with unmodified opinion(s) (free from any qualifications).
 - Details as per Regulation 52(4) of SEBI Listing Regulations.
- Declaration of interim dividend of Rs. 7.21/- (at the rate of 721%) on each fully paid-up equity share of Re. 1/- each for the Financial Year 2026-2027;

Further, the record date for determining the eligibility of shareholders for the payment of the interim dividend has been fixed as Friday, May 29, 2026. The payment of the interim dividend would be made to the eligible shareholders on or before June 19, 2026.

The meeting of the Board of Directors commenced at 11:00 A.M. and concluded at 02:30 P.M.

This is for your information and record.

Thanking You,

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer
Membership No: A26493

Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

Walker Chandiok & Co LLP

Block No. D/15th Floor,
Cabin No. A8 to A10
"West Gate" Near YMCA
Club, S.G Highway, Sarkhej
Road, Ahmedabad-380015
Gujarat, India

Independent Auditor's Report on Consolidated Annual Financial Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Eris Lifesciences Limited

Opinion

1. We have audited the accompanying consolidated annual financial results ('the Statement') of Eris Lifesciences Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), and joint venture for the year ended 31 March 2026, attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of other auditors on separate audited financial statements of the subsidiaries and joint venture, as referred to in paragraph 12 below, the Statement:
 - (i) includes the annual financial results of the entities listed in Annexure 1;
 - (ii) presents financial results in accordance with the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations, and
 - (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 ('the Act') read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the consolidated net profit after tax and other comprehensive income and other financial information of the Group and joint venture, for the year ended 31 March 2026.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in *the Auditor's Responsibilities for the Audit of the Statement* section of our report. We are independent of the Group and joint venture, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the consolidated financial results under the provisions of the Act, and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us together with the audit evidence obtained by the other auditors in terms of their reports referred to in paragraph 12 of the Other Matter section below, is sufficient and appropriate to provide a basis for our opinion.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiok & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Walker Chandiook & Co LLP

Independent Auditor's Report on Consolidated Annual Financial Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd).

Responsibilities of Management and Those Charged with Governance for the Statement

4. The Statement has been prepared on the basis of the consolidated annual financial statements and has been approved by the Holding Company's Board of Directors. The Holding Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the consolidated net profit and other comprehensive income, and other financial information of the Group including its joint venture in accordance with the Ind AS prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations. The respective Board of Directors of the companies included in the Group and joint venture, are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding of the assets of the Group, and joint venture, and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively, for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results, that give a true and fair view and are free from material misstatement, whether due to fraud or error. These financial results have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.
5. In preparing the Statement, the respective Board of Directors of the companies included in the Group and joint venture, are responsible for assessing the ability of the Group and joint venture, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting, unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.
6. Those respective Board of Directors are also responsible for overseeing the financial reporting process of the companies included in the Group and joint venture.

Auditor's Responsibilities for the Audit of the Statement

7. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act will always detect a material misstatement, when it exists. Misstatements can arise from fraud or error, and are considered material if, individually, or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
8. As part of an audit in accordance with the Standards on Auditing specified under section 143(10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls;



Chartered Accountants

Walker ChandioK & Co LLP

Independent Auditor's Report on Consolidated Annual Financial Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd).

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors;
 - Conclude on the appropriateness of Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and joint venture, to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and joint venture to cease to continue as a going concern;
 - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation; and
 - Obtain sufficient appropriate audit evidence regarding the financial statements of the entities or business activities within the Group, and joint venture, to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement, of which we are the independent auditors. For the other entities included in the Statement, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.
9. We communicate with those charged with governance of the Holding Company and such other entities included in the Statement, of which we are the independent auditors, regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
11. We also performed procedures in accordance with circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

Other Matter(s)

12. We did not audit the annual financial results of 6 subsidiaries included in the Statement whose financial information reflects total assets of ₹ 1,283.87 Crores as at 31 March 2026, total revenues of ₹ 545.48 Crores, total net profit after tax of ₹ 115.14 Crores, total comprehensive income of ₹ 113.44 Crores, and net cash outflows of ₹ 11.19 Crores for the year ended on that date, as considered in the Statement. The Statement also includes the Group's share of net profit after tax of ₹ 0.09 Crores and total comprehensive income of ₹ 0.09 Crores for the year ended 31 Month 2026, in respect of joint venture, whose annual financial statements have not been audited by us. These annual financial statements have been audited by other auditors whose audit reports have been furnished to us by the management, and our opinion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and joint venture is based solely on the audit reports of such other auditors, and the procedures performed by us as stated in paragraph 11 above.

Our opinion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.



Chartered Accountants

Walker ChandioK & Co LLP

Independent Auditor's Report on Consolidated Annual Financial Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd).

13. The Statement includes the consolidated financial results for the quarter ended 31 Month 2026, being the balancing figures between the audited consolidated figures in respect of the full financial year and the published unaudited year-to-date consolidated figures up to the third quarter of the current financial year, which were subject to limited review by us.
14. The audit of consolidated financial results for the year ended 31 March 2025 and review of unaudited consolidated financial results for the quarter ended 31 March 2025 included in the Statement was carried out and reported by Deloitte Haskins & Sells LLP who have expressed unmodified opinion vide their audit report dated 19 May 2025 and unmodified conclusion vide their review report dated 19 May 2025, respectively, whose report has been furnished to us and which has been relied upon by us for the purpose of our audit of the Statement. Our opinion is not modified in respect of this matter.

For Walker ChandioK & Co LLP

Chartered Accountants

Firm Registration No.: 001076N/N500013



Ashish Gupta

Partner

Membership No. 504662

UDIN: 26504662WQXJNA6913



Place: Ahmedabad

Date: 20 May 2026

Walker ChandioK & Co LLP

Independent Auditor's Report on Consolidated Annual Financial Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd).

Annexure 1 List of entities included in the Statement

| Sr. No. | Name of Entity | Relationship Type |
|---------|--|----------------------|
| 1 | Eris Lifesciences Limited | Holding Company |
| 2 | Eris Therapeutics Limited | Subsidiary |
| 3 | Aprica Healthcare Limited | Step-down Subsidiary |
| 4 | Eris Oaknet Healthcare Private Limited | Step-down Subsidiary |
| 5 | Eris Healthcare Private Limited | Subsidiary |
| 6 | Eris M. J. Biopharm Private Limited | Subsidiary |
| 7 | Eris Pharmaceuticals Limited (formerly Eris Pharmaceuticals Private Limited) | Subsidiary |
| 8 | Eris Bionxt Private Limited (formerly Chemman Labs Private Limited) | Subsidiary |
| 9 | Swiss Parenterals Limited | Subsidiary |
| 10 | Levim Lifetech Private Limited | Joint Venture |





Statement of Consolidated Financial results for the Quarter and Year ended March 31, 2026

| Sr. No. | Particulars | [Rs in Crore except per share data] | | | | |
|---------|---|-------------------------------------|----------------------------------|-----------------------------------|-----------------------------|-----------------------------|
| | | For Quarter ended | | | For year ended | |
| | | March 31, 2026 (Refer note 12) | December 31, 2025 (Unaudited) | March 31, 2025 (Refer Note 12) | March 31, 2026 (Audited) | March 31, 2025 (Audited) |
| 1 | Income | | | | | |
| | Revenue from operations | | | | | |
| | Sale of products | 752.29 | 800.89 | 702.60 | 3,114.89 | 2,879.26 |
| | Other operating income | 4.27 | 6.56 | 2.70 | 14.53 | 14.38 |
| | Total Revenue from operations | 756.56 | 807.45 | 705.30 | 3,129.42 | 2,893.64 |
| | Other income | 2.23 | 0.02 | 7.95 | 7.75 | 18.36 |
| | Total income | 758.79 | 807.47 | 713.25 | 3,137.17 | 2,912.00 |
| 2 | Expenses | | | | | |
| | Cost of materials consumed | 68.12 | 105.85 | 68.28 | 326.65 | 276.34 |
| | Purchase of stock-in-trade | 122.97 | 117.24 | 95.98 | 490.56 | 473.12 |
| | Changes in inventories of finished goods, stock-in-trade and work-in-progress | (5.84) | 0.21 | 5.99 | (21.61) | (35.47) |
| | Employee benefits expense | 136.85 | 138.08 | 121.45 | 556.81 | 505.09 |
| | Finance costs | 45.62 | 48.82 | 54.28 | 192.67 | 231.29 |
| | Depreciation and amortisation expense | 69.57 | 70.34 | 77.25 | 279.50 | 315.46 |
| | Other expenses | 160.89 | 164.46 | 161.21 | 656.90 | 657.36 |
| | Total expenses | 598.18 | 645.00 | 584.44 | 2,481.48 | 2,423.19 |
| 3 | Profit before share of profit from investment in joint venture, exceptional item and tax for the period / year (1-2) | 160.61 | 162.47 | 128.81 | 655.69 | 488.81 |
| 4 | Share of loss/ (profit) from investment in joint venture, net of tax | 1.20 | (0.12) | (0.06) | (0.09) | (0.06) |
| 5 | Profit before exceptional item and tax for the period / year (3-4) | 159.41 | 162.59 | 128.75 | 655.78 | 488.75 |
| 6 | Exceptional items (Refer note 5) | - | 17.24 | - | 17.24 | - |
| 7 | Profit before tax for the period / year (5-6) | 159.41 | 145.35 | 128.75 | 638.54 | 488.75 |
| 8 | Tax Expense | | | | | |
| | Current tax | 12.49 | 17.43 | 31.39 | 157.41 | 111.84 |
| | Deferred tax (Refer note 11) | (132.18) | 19.09 | (4.87) | (166.38) | 2.36 |
| | Total tax expense | (119.69) | 36.52 | 26.52 | (8.97) | 114.20 |
| 9 | Net profit for the period / year (7-8) | 279.10 | 108.83 | 102.35 | 647.51 | 374.67 |
| | Attributable to : | | | | | |
| | - Owners of the Company | 281.61 | 99.72 | 93.84 | 619.52 | 351.84 |
| | - Non controlling interest | (2.51) | 9.11 | 8.51 | 27.99 | 22.83 |
| 10 | Other comprehensive income/(loss) | | | | | |
| | Items that will not be reclassified to profit or loss | | | | | |
| | Re-measurement gains / (losses) on defined benefit plans | 2.64 | (0.84) | (1.62) | 0.12 | (3.63) |
| | Income tax effect | (0.59) | 0.27 | (0.33) | 0.22 | 0.34 |
| | Items that will be reclassified to profit or loss | | | | | |
| | Net movement on effective portion of cash flow hedges | (2.21) | (0.21) | - | (2.42) | - |
| | Income tax effect | 0.60 | 0.04 | - | 0.64 | - |
| | Other comprehensive income/(loss) for the period / year, net of tax | 0.44 | (0.74) | (1.95) | (1.44) | (3.29) |
| | Attributable to : | | | | | |
| | - Owners of the Company | 0.35 | (0.70) | (1.84) | (1.47) | (3.18) |
| | - Non controlling interest | 0.09 | (0.04) | (0.11) | 0.03 | (0.11) |
| 11 | Total comprehensive income | | | | | |
| | Attributable to : | | | | | |
| | - Owners of the Company | 281.96 | 99.02 | 92.00 | 618.05 | 348.66 |
| | - Non controlling interest | (2.42) | 9.07 | 8.40 | 28.02 | 22.72 |
| | Total comprehensive income for the period / year (9+10) | 279.54 | 108.09 | 100.40 | 646.07 | 371.38 |
| 12 | Paid Up Equity Share Capital (Face Value of Rs 1 each) | 13.85 | 13.62 | 13.62 | 13.85 | 13.62 |
| 13 | Other Equity | | | | 3,888.82 | 2,840.74 |
| 14 | Earnings Per Share (of Rs 1 each) (not annualised) : | | | | | |
| | Basic | 20.60 | 7.32 | 6.90 | 45.33 | 25.85 |
| | Diluted | 20.57 | 7.31 | 6.89 | 45.26 | 25.81 |

Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad - 380054
 Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

Statement of Consolidated Assets and Liabilities as at March 31, 2026

[Rs in Crore]

| Particulars | As at March 31, 2026 | As at March 31, 2025 |
|--|-------------------------|-------------------------|
| | (Audited) | (Audited) |
| I. ASSETS : | | |
| Non Current Assets | | |
| (a) Property, plant and equipment | 661.52 | 604.89 |
| (b) Capital work in progress | 171.47 | 66.74 |
| (c) Right-of-use assets | 46.85 | 57.18 |
| (d) Goodwill | 911.97 | 911.97 |
| (e) Other intangible assets | 3,567.22 | 3,732.44 |
| (f) Intangible assets under development | - | 0.27 |
| (g) Investments accounted using equity method | 51.58 | 51.49 |
| (h) Financial assets | | |
| (i) Investments | 9.98 | 10.51 |
| (ii) Loans | 1.12 | 1.08 |
| (iii) Other financial assets | 9.83 | 10.81 |
| (i) Non current tax assets (net) | 40.66 | 39.54 |
| (j) Deferred tax assets (net) | 242.91 | 289.04 |
| (k) Other non-current assets | 110.55 | 34.22 |
| Total Non-current assets | 5,825.66 | 5,810.18 |
| Current assets | | |
| (a) Inventories | 436.82 | 334.83 |
| (b) Financial assets | | |
| (i) Investments | - | 5.00 |
| (ii) Trade receivables | 680.34 | 458.64 |
| (iii) Cash and cash equivalents | 54.74 | 199.74 |
| (iv) Bank balances other than (iii) above | 12.56 | 23.09 |
| (v) Loans | 52.75 | 5.78 |
| (vi) Other financial assets | 9.08 | 3.19 |
| (c) Other current assets | 293.56 | 195.96 |
| Total Current assets | 1,539.85 | 1,226.23 |
| TOTAL- ASSETS | 7,365.51 | 7,036.41 |
| II. EQUITY AND LIABILITIES : | | |
| Equity | | |
| (a) Equity share capital | 13.850 | 13.62 |
| (b) Other equity | 3,888.82 | 2,840.74 |
| Equity attributable to the owners of the company | 3,902.67 | 2,854.36 |
| (c) Non-controlling interest | (7.01) | 417.40 |
| Total Equity | 3,895.66 | 3,271.76 |
| Non-current liabilities | | |
| (a) Financial liabilities | | |
| (i) Borrowings | 955.83 | 1,737.51 |
| (ii) Lease liabilities | 40.19 | 44.21 |
| (iii) Other financial liabilities | 1.07 | 6.40 |
| (b) Other non-current liabilities | 3.80 | 4.47 |
| (c) Provisions | 86.78 | 68.98 |
| (d) Deferred tax liabilities (net) | 305.08 | 518.45 |
| Total Non-Current liabilities | 1,392.75 | 2,380.02 |
| Current liabilities | | |
| (a) Financial Liabilities | | |
| (i) Borrowings | 1,353.85 | 684.15 |
| (ii) Lease liabilities | 8.75 | 12.05 |
| (iii) Trade payables | | |
| i) Total outstanding dues of micro enterprises and small enterprises | 8.76 | 15.98 |
| ii) Total outstanding dues of creditors other than micro enterprises and small enterprises | 320.89 | 316.37 |
| (iv) Other financial liabilities | 197.74 | 165.14 |
| (b) Other current liabilities | 71.64 | 69.24 |
| (c) Provisions | 37.71 | 78.09 |
| (d) Income tax liabilities (net) | 77.76 | 43.61 |
| Total Current liabilities | 2,077.10 | 1,384.63 |
| Total liabilities | 3,469.85 | 3,764.65 |
| TOTAL- EQUITY AND LIABILITIES | 7,365.51 | 7,036.41 |



Statement of Consolidated Cash Flows for the year ended March 31, 2026

[Rs in Crore]

| Particulars | March 31, 2026 | March 31, 2025 |
|--|-----------------|-----------------|
| | (Audited) | (Audited) |
| A. Cash flow from operating activities | | |
| Profit before tax | 638.54 | 488.87 |
| Adjustments for : | | |
| Depreciation and amortisation expense | 279.50 | 315.46 |
| Net loss on property plant and equipment | 0.04 | 0.92 |
| Finance costs | 192.67 | 231.29 |
| Interest income | (3.47) | (5.06) |
| Share of profit of a joint venture, net of tax | (0.09) | (0.06) |
| Exceptional items | 17.24 | - |
| Reversal of expected credit loss | (10.70) | - |
| Deferred capital subsidy | (0.65) | (0.63) |
| Net (gain) on sale of investments carried at fair value through profit or loss | (0.68) | (3.00) |
| Share based payment expense | 8.00 | 9.13 |
| Operating profit before working capital changes | 1,120.40 | 1,036.92 |
| Changes in working capital: | | |
| Adjustments for (increase) / decrease in operating assets: | | |
| Trade receivables | (210.30) | (9.11) |
| Inventories | (100.66) | (94.36) |
| Financial assets | (3.66) | (2.51) |
| Other assets | (99.46) | 121.97 |
| Adjustments for increase / (decrease) in operating liabilities: | | |
| Trade payables | (3.16) | 67.94 |
| Financial liabilities | (3.19) | 0.99 |
| Provisions | (39.97) | 24.27 |
| Other liabilities | 2.37 | 16.78 |
| Cash generated from operations | 662.37 | 1,162.89 |
| Net income tax paid | (124.38) | (97.88) |
| Net cash generated from operating activities (A) | 537.99 | 1,065.01 |
| B. Cash flow from investing activities | | |
| Purchase of property, plant and equipment (including intangible assets, intangible assets under development, capital advances and capital creditors) | (296.86) | (155.00) |
| Proceeds from sale of property plant and equipment | 0.09 | 0.37 |
| Receipt of government grants | - | 3.88 |
| Consideration paid towards investment in Joint venture | - | (51.43) |
| Consideration paid towards business combination (Including transaction costs) | (10.00) | (1,169.00) |
| Proceeds from redemption of mutual funds (net) | 0.68 | 3.00 |
| Proceeds from redemption of investment in bonds | 5.54 | - |
| Investments in compulsory convertible debentures purchased from minority interest in subsidiary | (34.65) | - |
| Loan given to joint venture | (47.01) | (0.25) |
| Proceeds of bank balances not considered as cash and cash equivalents | 10.53 | 1,284.03 |
| Interest received | 2.22 | 4.43 |
| Net cash used in investing activities (B) | (369.46) | (79.97) |
| C. Cash flow from financing activities | | |
| Proceeds from long term borrowings | 117.28 | 1,400.00 |
| Repayment of long term borrowings | (282.26) | (798.89) |
| Proceeds/ (repayment) from short term borrowings (net) | 53.00 | (998.32) |
| Interest paid | (193.28) | (145.06) |
| Principal element to lease payment | (12.75) | (8.72) |
| Proceeds from issue of equity share capital (Employee stock options plan) | 4.48 | 7.22 |
| Payment towards acquisition of the non-controlling interest | - | (237.50) |
| Dividend paid | - | (100.05) |
| Net cash used in financing activities (C) | (313.53) | (881.32) |
| Net increase/(decrease) in cash and cash equivalents (A+B+C) | (145.00) | 103.72 |
| Cash and cash equivalents at the beginning of the year | 199.74 | 94.25 |
| Cash and cash equivalents acquired pursuant to business acquisition | - | 1.77 |
| Cash and cash equivalents at end of the year | 54.74 | 199.74 |



Additional information pursuant to Regulation 52(4) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 as amended for the quarter and year ended March 31, 2026

| Particulars | Quarter ended | | | For year ended | |
|--|-----------------------------------|-------------------------------------|-----------------------------------|-----------------------------|-----------------------------|
| | March 31, 2026 (Refer note 12) | December 31, 2025 (Unaudited) | March 31, 2025 (Refer Note 12) | March 31, 2026 (Audited) | March 31, 2025 (Audited) |
| Debt – Equity Ratio (in times) (Total Debt(including lease liabilities)/Total Equity) | 0.61 | 0.67 | 0.76 | 0.61 | 0.76 |
| Debt Service Coverage Ratio (in times) (Profit after tax-Other income+ Depreciation and amortisation expense+Finance Costs+Committed Principal repayments made during the period for long term loans/Finance Costs +Committed Principal repayments made during the period for long term loans) | 3.95 | 2.48 | 2.36 | 2.91 | 2.24 |
| Interest service coverage ratio (in times) (Earnings before share of profit from joint venture, exceptional items, Interest and Tax/Finance Costs) | 4.52 | 4.33 | 3.37 | 4.40 | 3.11 |
| Outstanding redeemable preference shares (quantity and value) | NA | NA | NA | NA | NA |
| Capital redemption reserve/debenture redemption reserve (Rs in crore) | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 |
| Net worth (Rs in crore) | 3,895.66 | 3,610.87 | 3,271.76 | 3,895.66 | 3,271.76 |
| Net profit after tax (Rs in crore) | 279.10 | 108.83 | 102.35 | 647.51 | 374.67 |
| Earnings per share | | | | | |
| Basic | 20.60 | 7.32 | 6.90 | 45.33 | 25.85 |
| Diluted | 20.57 | 7.31 | 6.89 | 45.26 | 25.81 |
| Current Ratio (in times) (Current Assets/Current Liabilities) | 0.74 | 0.69 | 0.89 | 0.74 | 0.89 |
| Long term debt to working capital (in times) (Long-term borrowing+Lease liabilities including its current maturity/Current Assets-Current liabilities (excluding current maturity)) | 5.13 | 7.67 | 14.74 | 5.13 | 14.74 |
| Bad debts to account receivable ratio (in times) (Bad debts/Trade receivables) | Nil | Nil | NIL | Nil | NIL |
| Current liability ratio (in times) (Current liabilities/Total liabilities) | 0.60 | 0.60 | 0.37 | 0.60 | 0.37 |
| Total debts to total assets (in times) (Total Debt (including lease liabilities)/Total Assets) | 0.32 | 0.33 | 0.35 | 0.32 | 0.35 |
| Debtors' turnover* (in times) (Sales/Trade receivables) | 4.58 | 4.27 | 6.28 | 4.58 | 6.28 |
| Inventory Turnover* (in times) (Cost of goods sold/Average Inventory) | 2.06 | 2.24 | 2.73 | 2.06 | 2.73 |
| Operating margin percent (Earnings before share of profit/ (loss) from joint venture, exceptional items, Interest and Tax/Revenue from Operations) | 27.26% | 26.17% | 25.96% | 27.11% | 24.89% |
| Net profit margin percent (Profit after tax/Revenue from Operations) | 36.89% | 13.48% | 14.51% | 20.69% | 12.95% |

*Quarterly ratios based on trailing twelve months values.



Notes to Consolidated Financial results

- 1 The above statement of Audited Consolidated Financial results ("the Statement") have been recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 20, 2026.
- 2 These consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act 2013 ('the Act') read with Companies (Indian Accounting Standards) Rules 2015 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 (as amended).
- 3 The Holding Company has issued and allotted 73,946 ordinary shares of Rs 1 each under the Company's Employee Stock Option Scheme 2021 during the year ended March 31, 2026.
- 4 The Holding Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".
- 5 Effective November 21, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. The Holding Company has assessed the financial implications of these changes which has resulted in increase in gratuity liability and leave liability arising out of past service cost by Rs 17.24 Crores primarily arising due to change in definition of "wages" for employees and contract labours. The Holding Company has presented such incremental impact under "Exceptional Item" in the consolidated financial results for the year ended March 31, 2026.
- 6 The Holding Company on January 16, 2026, completed the acquisition of 16,74,493 fully paid equity shares of Swiss Parenteral Limited (SPL), which represented the whole of remaining minority shares in the subsidiary. With this acquisition, SPL has become a wholly owned subsidiary. The total purchase consideration was discharged by the Holding Company through the issue of its equity shares on a preferential basis.
- 7 During the previous year ended March 31, 2025, the Holding Company has acquired 1,43,13,418 equity shares representing 100% of the equity share capital of Eris Bionxt Private Limited (formerly known as Chemman Labs Private Limited), from its erstwhile shareholders for a consideration of Rs. 27 Crores. The transaction achieved closure in October 2024, on completion of all relevant conditions precedent to the transaction. The Holding Company has completed the final determination of fair values of identified assets and liabilities for the purpose of Purchase Price Allocation for the aforesaid acquisitions during the period, consequently there is no material changes in the provisional fair valuation report which was earlier accounted as part of Business Combination.
- 8 During the previous year ended March 31, 2025, the Holding Company sold its equity investment in Eris Oaknet Healthcare Private Limited (EOHPL) and Aprica Healthcare Limited (AHL) to Eris Therapeutics Limited (ETL). As a result, EOHPL and AHL are now a wholly owned subsidiary of ETL.

During the year ended March 31, 2026, taking into account the revised shareholding structure and other relevant factors arising from the above-mentioned transfer of stake, the ETL proposed the scheme whereby the "Domestic Business" of EOHPL shall get vested into ETL ("Resulting Company/Amalgamated Company") and AHL ("Amalgamating Company") would be amalgamated with ETL. The respective Boards of Directors of ETL, AHL, and EOHPL have approved the Composite Scheme of Arrangement under Sections 230 to 232, read with Section 66 and other applicable provisions of the Companies Act, 2013. The Scheme is subject to necessary statutory and regulatory approvals, as required under applicable laws.

- 9 The Board of Directors of the Holding Company has declared an interim dividend of Rs 7.21/- (at the rate of 721 Percent) per equity share of the face value of Re. 1/- each for the financial year 2026-27 at its meeting held on May 20, 2026.
- 10 During the quarter and year ended March 31, 2026, the Holding Company has completed acquisition of the Branded Probiotics Business from Velbiom Probiotics Private Limited for a consideration of Rs 50 Crores on a slump sale basis. The acquisition was completed on March 31, 2026. The Holding Company is in the process of making final determination of fair values of identified assets and liabilities for the purpose of purchase price allocation.
- 11 The Holding Company under the Income tax act, 2025 is eligible to opt for the concessional tax regime from the financial year 2026-27. In accordance with Ind AS 12 Income taxes, deferred tax assets and liabilities are measured using the tax rates that are enacted or substantively enacted as at the reporting date. Accordingly, during the quarter and year ended 31 March 2026, the Holding Company remeasured its deferred tax assets and liabilities based on the revised tax rate. This has resulted in an impact of deferred tax credit of Rs 150 Crores being recognized in the statement of profit and loss.
- 12 The figures for the quarter ended March 31, 2026 and March 31, 2025 are balancing figures between the audited figures in respect of full financial year up to March 31, 2026 and March 31, 2025 and unaudited published year-to-date figures up to third quarter ended December 31, 2025 and December 31, 2024 respectively, which were subjected to limited review by the statutory auditors.



For Eris Lifesciences Limited

Amit Bakshi
Chairman and Managing Director
DIN : 01250925

Place: Ahmedabad
Date: May 20, 2026

Independent Auditor's Report on Standalone Annual Financial Results of the Company Pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Eris Lifesciences Limited

Opinion

1. We have audited the accompanying standalone annual financial results ('the Statement') of Eris Lifesciences Limited ('the Company') for the year ended 31 March 2026, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - (i) presents financial results in accordance with the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations, and
 - (ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 ('the Act'), read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the standalone net profit after tax and other comprehensive income and other financial information of the Company for the year ended 31 March 2026.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Statement* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Those Charged with Governance for the Statement

4. This Statement has been prepared on the basis of the standalone annual financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the Ind AS specified under section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India, and in compliance with Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Walker Chandiook & Co LLP

Independent Auditor's Report on Standalone Annual Financial Results of the Company Pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

5. In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Statement

7. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
8. As part of an audit in accordance with the Standards on Auditing, specified under section 143(10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place an adequate internal financial controls with reference to financial statements and the operating effectiveness of such controls;
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors;
 - Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern; and
 - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.



Walker Chandiook & Co LLP

Independent Auditor's Report on Standalone Annual Financial Results of the Company Pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

9. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter(s)

11. The Statement includes the financial results for the quarter ended 31 March 2026, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subject to limited review by us.
12. The audit of standalone financial results for the year ended 31 March 2025 and review of unaudited standalone financial results for the quarter ended 31 March 2025 included in the Statement was carried out and reported by Deloitte Haskins & Sells LLP who have expressed unmodified opinion vide their audit report dated 19 May 2025 and unmodified conclusion vide their review report dated 19 May 2025, respectively, whose report has been furnished to us and which has been relied upon by us for the purpose of our audit of the Statement. Our opinion is not modified in respect of this matter.

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No.: 001076N/N500013


Ashish Gupta

Partner

Membership No. 504662

UDIN: 26504662SENQOQ5754



Place: Ahmedabad

Date: 20 May 2026



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013

Eris
Eris Lifesciences Limited

Statement of Standalone Financial Results for the Quarter and Year Ended March 31, 2026

| Sr. No. | Particulars | [Rs. in Crore except per share data] | | | | |
|---------|---|--------------------------------------|----------------------------------|-----------------------------------|-----------------------------|-----------------------------|
| | | For Quarter ended | | | For Year ended | |
| | | March 31, 2026 (Refer Note 10) | December 31, 2025 (Unaudited) | March 31, 2025 (Refer Note 10) | March 31, 2026 (Audited) | March 31, 2025 (Audited) |
| 1 | Income | | | | | |
| | Revenue from Operations | | | | | |
| | Sale of products | 267.52 | 306.78 | 395.71 | 1,779.77 | 1,663.63 |
| | Other operating income | 9.79 | 8.51 | 9.06 | 41.97 | 34.12 |
| | Total Revenue from Operations | 277.31 | 315.29 | 404.77 | 1,821.74 | 1,697.75 |
| | Other Income | 26.97 | 25.07 | 16.75 | 98.31 | 35.51 |
| | Total Income | 304.28 | 340.36 | 421.52 | 1,920.05 | 1,733.26 |
| 2 | Expenses | | | | | |
| | Cost of materials consumed | 22.53 | 17.05 | 9.83 | 83.99 | 68.35 |
| | Purchase of stock-in-trade | 122.95 | 113.75 | 119.02 | 478.22 | 474.44 |
| | Changes in inventories of finished goods, stock-in-trade and work-in- progress | (7.72) | (20.77) | (4.53) | 64.49 | (43.54) |
| | Employee benefits expense | 78.67 | 82.75 | 81.41 | 340.62 | 361.92 |
| | Finance costs | 42.70 | 45.20 | 53.16 | 179.54 | 220.24 |
| | Depreciation and amortisation expense | 38.82 | 38.66 | 43.38 | 154.38 | 181.77 |
| | Other expenses | 39.10 | 45.16 | 78.07 | 242.09 | 350.03 |
| | Total expenses | 337.05 | 321.80 | 380.34 | 1,543.33 | 1,613.21 |
| 3 | Profit/ (loss) before exceptional items and tax for the period / year(1-2) | (32.77) | 18.56 | 41.18 | 376.72 | 120.05 |
| 4 | Exceptional items (Refer note 4) | - | 14.67 | - | 14.67 | - |
| 5 | Profit/ (loss) before tax for the period / year (3-4) | (32.77) | 3.89 | 41.18 | 362.05 | 120.05 |
| 6 | Tax expense | | | | | |
| | Current tax | (7.63) | 0.51 | 8.51 | 60.96 | 21.98 |
| | Deferred tax (Refer note 9) | (16.54) | 0.29 | 2.20 | 57.04 | 20.68 |
| | Total tax expense | (24.17) | 0.80 | 10.71 | 118.00 | 42.66 |
| 7 | Net profit/ (loss) for the period / year (5-6) | (8.60) | 3.09 | 30.47 | 244.05 | 77.39 |
| 8 | Other Comprehensive income/ (loss) | | | | | |
| | Items that will not be reclassified to profit or (loss) | | | | | |
| | Re-measurement gains / (losses) on defined benefit plans | 2.96 | (0.77) | (1.18) | 0.65 | (3.10) |
| | Income tax effect | (0.77) | 0.27 | (0.41) | 0.04 | 0.26 |
| | Other Comprehensive income/(loss) for the period / year, net of tax | 2.19 | (0.50) | (1.59) | 0.69 | (2.84) |
| 9 | Total Comprehensive (loss) / income for the period / year (7+8) | (6.41) | 2.59 | 28.88 | 244.74 | 74.55 |
| 10 | Paid Up Equity Share Capital (Face Value of Rs 1 each) | 13.85 | 13.62 | 13.62 | 13.85 | 13.62 |
| 11 | Other Equity | | | | 3,181.61 | 2,501.28 |
| 12 | Earnings/(Loss) Per Share (of Rs 1 each) (not annualised) : | | | | | |
| | Basic | (0.63) | 0.23 | 2.24 | 17.86 | 5.69 |
| | Diluted | (0.63) | 0.23 | 2.23 | 17.83 | 5.68 |



Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

Statement of Standalone Assets and Liabilities as at March 31, 2026

[Rs in Crore]

| Particulars | As at March 31, 2026 (Audited) | As at March 31, 2025 (Audited) |
|---|--------------------------------------|--------------------------------------|
| I. ASSETS : | | |
| Non Current Assets | | |
| (a) Property, plant and equipment | 99.64 | 74.70 |
| (b) Right-of-use asset | 24.55 | 32.47 |
| (c) Goodwill | 48.57 | 48.57 |
| (d) Other intangible assets | 2,179.79 | 2,256.44 |
| (e) Intangible assets under development | - | 0.27 |
| (f) Financial assets | | |
| (i) Investments | 1,414.05 | 991.27 |
| (ii) Loans | 456.51 | 249.11 |
| (iii) Other financial asset | 265.93 | 639.06 |
| (g) Non current tax assets (net) | 30.02 | 12.64 |
| (h) Deferred tax assets (net) | 226.36 | 283.36 |
| (i) Other non-current assets | 9.71 | 7.00 |
| Total Non Current Assets | 4,755.13 | 4,594.89 |
| Current Assets | | |
| (a) Inventories | 121.36 | 191.25 |
| (b) Financial assets | | |
| (i) Trade receivables | 307.16 | 236.19 |
| (ii) Cash and cash equivalents | 25.18 | 84.34 |
| (iii) Bank balances other than (ii) above | 2.58 | 8.12 |
| (iv) Loans | 500.34 | 14.01 |
| (v) Other financial asset | 2.98 | 7.20 |
| (c) Other current assets | 63.21 | 86.43 |
| Total Current Assets | 1,022.81 | 627.54 |
| TOTAL- ASSETS | 5,777.94 | 5,222.43 |
| II. EQUITY AND LIABILITIES : | | |
| Equity | | |
| (a) Equity share capital | 13.85 | 13.62 |
| (b) Other equity | 3,181.61 | 2,501.28 |
| Total equity | 3,195.46 | 2,514.90 |
| Non Current Liabilities | | |
| (a) Financial liabilities | | |
| (i) Borrowings | 797.62 | 1,632.64 |
| (ii) Lease Liabilities | 19.72 | 22.01 |
| (b) Other non-current liabilities | 0.48 | 0.96 |
| (c) Provisions | 46.93 | 57.98 |
| Total Non Current Liabilities | 864.75 | 1,713.59 |
| Current Liabilities | | |
| (a) Financial Liabilities | | |
| (i) Borrowings | 1,277.94 | 580.31 |
| (ii) Lease liabilities | 5.86 | 9.91 |
| (iii) Trade payables | | |
| A) Total outstanding dues of micro enterprises and small enterprises | 5.13 | 3.06 |
| B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 214.22 | 213.02 |
| (iv) Other financial liabilities | 160.87 | 126.77 |
| (b) Other current liabilities | 25.91 | 15.95 |
| (c) Provisions | 27.80 | 39.26 |
| (d) Income tax liabilities (net) | - | 5.66 |
| Total Current liabilities | 1,717.73 | 993.94 |
| Total liabilities | 2,582.48 | 2,707.53 |
| TOTAL- EQUITY AND LIABILITIES | 5,777.94 | 5,222.43 |



Standalone Statement of Cash Flows for the year ended March 31, 2026

[Rs in Crore]

| Particulars | For the year ended | |
|--|--------------------|-----------------|
| | March 31, 2026 | March 31, 2025 |
| | (Audited) | (Audited) |
| A. Cash flow from operating activities | | |
| Profit before tax | 362.05 | 120.05 |
| Adjustments for : | | |
| Depreciation and amortisation expense | 154.38 | 181.77 |
| Net Loss on property plant and equipment | 0.04 | 0.91 |
| Finance costs | 179.54 | 220.24 |
| Exceptional items | 14.67 | - |
| Interest income | (78.48) | (15.05) |
| Reversal of expected credit loss | (13.84) | - |
| Deferred capital subsidy | (0.46) | (0.44) |
| Net (gain) on sale of investments carried at fair value through profit or loss | (0.68) | (3.00) |
| Share based payment expense | 8.00 | 9.13 |
| Operating profit before working capital changes | 625.22 | 513.61 |
| Changes in working capital: | | |
| Adjustments for (increase) / decrease in operating assets: | | |
| Trade receivables | (56.43) | 31.31 |
| Inventories | 71.22 | (49.47) |
| Financial assets | 2.04 | - |
| Other assets | 21.36 | 136.03 |
| Adjustments for increase / (decrease) in operating liabilities: | | |
| Trade payables | 2.81 | 78.94 |
| Financial liabilities | (0.49) | (0.37) |
| Provisions | (36.80) | 7.40 |
| Other liabilities | 9.94 | (2.15) |
| Cash generated from operations | 638.87 | 715.30 |
| Net income tax paid | (74.93) | (13.43) |
| Net cash flow from operating activities (A) | 563.94 | 701.86 |
| B. Cash flow from investing activities | | |
| Purchase of property, plant and equipment (including intangible assets, intangible assets under development, capital advances and capital creditors) | (49.39) | (7.62) |
| Proceeds from sale of property plant and equipment | 0.09 | 0.12 |
| Consideration paid towards business combination | (10.00) | (1,142.00) |
| Consideration paid towards investment in subsidiaries | - | (264.50) |
| Proceeds from redemption of mutual funds (net) | 0.68 | 3.00 |
| Proceeds from redemption of investments in bonds of subsidiaries | - | 20.00 |
| Loan given to subsidiaries | (799.06) | (280.08) |
| Loan repaid by subsidiaries | 143.90 | 73.49 |
| Loan given to others received back | - | 0.20 |
| Proceeds/ (Investments) in fixed deposit (net) | 5.54 | (7.92) |
| Proceeds of Bank balances not considered as cash and cash equivalents | - | 1,245.20 |
| Interest income | 14.08 | 1.12 |
| Net cash used in investing activities (B) | (694.16) | (358.99) |
| C. Cash flow from financing activities | | |
| Proceeds/(repayment) from short term borrowings (net) | 62.44 | (1,077.00) |
| Proceeds of long term borrowings | - | 1,400.00 |
| Repayment of long term borrowings | (222.66) | (685.39) |
| Consideration received from sales of investment in subsidiaries | 402.30 | 240.00 |
| Proceeds of borrowings from subsidiaries | 40.34 | 390.40 |
| Repayment of borrowings to subsidiaries | (27.16) | (354.29) |
| Interest paid | (181.16) | (125.20) |
| Principal element to lease payment | (7.52) | (6.16) |
| Proceeds from issue of equity share capital (employee stock options plan) | 4.48 | 7.23 |
| Dividend paid | - | (100.05) |
| Net cash flow (from)/ used in financing activities (C) | 71.06 | (310.46) |
| Net increase/(decrease) in cash and cash equivalents (A+B+C) | (59.16) | 32.41 |
| Cash and cash equivalents at the beginning of the year | 84.34 | 51.93 |
| Cash and cash equivalents at end of the year | 25.18 | 84.34 |



Additional information pursuant to Regulation 52(4) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 as amended for the quarter and year ended March 31, 2026

| Particulars | Quarter ended | | | For Year ended | |
|--|-----------------------------------|----------------------------------|-----------------------------------|-----------------------------|-----------------------------|
| | March 31, 2026 (Refer Note 10) | December 31, 2025 (Unaudited) | March 31, 2025 (Refer Note 10) | March 31, 2026 (Audited) | March 31, 2025 (Audited) |
| Debt – Equity Ratio (in times) (Total Debt(including lease liabilities)/Total Equity) | 0.66 | 0.77 | 0.89 | 0.66 | 0.89 |
| Debt Service Coverage Ratio (in times) (Profit after tax-Other income+ Depreciation and amortisation expense+Finance Costs+Committed Principal repayments made during the period for long term loans/Finance Costs +Committed Principal repayments made during the period for long term loans) | 1.03 | 1.16 | 1.52 | 1.74 | 1.48 |
| Interest service coverage ratio (in times) (Earnings before exceptional items, Interest and Tax/Finance Costs) | 0.23 | 1.41 | 1.77 | 3.10 | 1.55 |
| Outstanding redeemable preference shares (quantity and value) | NA | NA | NA | NA | NA |
| Capital redemption reserve/debenture redemption reserve (Rs in crore) | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 |
| Net worth (Rs in crore) | 3,195.46 | 2,775.38 | 2,514.90 | 3,195.46 | 2,514.90 |
| Net (loss)/profit after tax (Rs in crore) | (8.60) | 3.09 | 30.47 | 244.05 | 77.39 |
| Earnings/ (loss) per share | | | | | |
| Basic | (0.63) | 0.23 | 2.24 | 17.86 | 5.69 |
| Diluted | (0.63) | 0.23 | 2.23 | 17.83 | 5.68 |
| Current Ratio (in times) (Current Assets/Current Liabilities) | 0.60 | 0.59 | 0.63 | 0.60 | 0.63 |
| Long term debt to working capital (in times) (Long-term borrowing+Lease liabilities including its current maturity/Current Assets-Current liabilities (excluding current maturity)) | 11.28 | 13.32 | (14.23) | 11.28 | (14.23) |
| Bad debts to account receivable ratio (in times) (Bad debts/ Trade receivables) | Nil | Nil | Nil | Nil | Nil |
| Current liability ratio (in times) (Current liabilities/Total liabilities) | 0.67 | 0.67 | 0.37 | 0.67 | 0.37 |
| Total debts to total assets (in times) (Total Debt (including lease liabilities)/Total Assets) | 0.36 | 0.40 | 0.43 | 0.36 | 0.43 |
| Debtors' turnover* (in times) (Sales/ Trade receivables) | 5.79 | 3.74 | 7.04 | 5.79 | 7.04 |
| Inventory Turnover* (in times) (Cost of goods sold/Average Inventory) | 4.01 | 4.19 | 3.53 | 4.01 | 3.53 |
| Operating margin percent (Earnings before exceptional items, Interest and Tax/Revenue from Operations) | 3.58% | 20.22% | 23.31% | 30.53% | 20.04% |
| Net (loss)/profit margin percent (Loss/Profit after tax/Revenue from Operations) | (3.10%) | 0.98% | 7.53% | 13.40% | 4.56% |


*Quarterly ratios based on trailing twelve months values.



Notes to Standalone Financial results

- 1 The above statement of Audited Standalone Financial results ("the Statement") have been recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 20, 2026.
- 2 These standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act 2013 ('the Act') read with Companies (Indian Accounting Standards) Rules 2015 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 (as amended).
- 3 The Company has issued and allotted 73,946 ordinary shares of Rs 1 each under the Company's Employee Stock Option Scheme 2021 during the year ended March 31, 2026.
- 4 Effective November 21, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. The Company has assessed the financial implications of these changes which has resulted in increase in gratuity liability and leave liability arising out of past service cost by Rs 14.67 Crores primarily arising due to change in definition of "wages" for employees and contract labours. The Company has presented such incremental impact under "Exceptional Item" in the standalone financial results for the year ended March 31, 2026.
- 5 The Company on January 16, 2026, completed the acquisition of 16,74,493 fully paid equity shares of Swiss Parenteral Limited (SPL), which represented the whole of remaining minority shares in the subsidiary. With this acquisition, SPL has become a wholly owned subsidiary. The total purchase consideration was discharged by the Company through the issue of its equity shares on a preferential basis.
- 6 The Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".
- 7 The Board of Directors of the Company has declared an interim dividend of Rs 7.21/- (at the rate of 721 Percent) per equity share of the face value of Re. 1/- each for the financial year 2026-27 at its meeting held on May 20, 2026.
- 8 During the quarter and year ended March 31, 2026, the Company has completed acquisition of the Branded Probiotics Business from Velbiom Probiotics Private Limited for a consideration of Rs 50 Crores on a slump sale basis. The acquisition was completed on March 31, 2026. The Company is in the process of making final determination of fair values of identified assets and liabilities for the purpose of purchase price allocation.
- 9 The Company under the Income Tax Act 2025 is eligible to opt for the concessional tax regime from the financial year 2026-27. In accordance with Ind AS 12 Income taxes, deferred tax assets and liabilities are measured using the tax rates that are enacted or substantively enacted as at the reporting date. Accordingly, during the quarter and year ended 31 March 2026, the Company remeasured its deferred tax assets and liabilities based on the revised tax rate applicable. This has resulted in an impact of deferred tax credit of Rs 18 Crores being recognized in the statement of profit and loss.
- 10 The figures for the quarter ended March 31, 2026 and March 31, 2025 are balancing figures between the audited figures in respect of full financial year up to March 31, 2026 and March 31, 2025 and unaudited published year-to-date figures up to third quarter ended December 31, 2025 and December 31, 2024 respectively, which were subjected to limited review by the statutory auditors.

For Eris Lifesciences Limited,



Amit Bakshi
Chairman and Managing Director
DIN : 01250925

Place: Ahmedabad
Date: May 20, 2026